Theravance Biopharma leans heavily on one key medicine, and growing pressure from governments and insurers on drug prices could make that strength harder to sustain. A late-stage drug readout and new partnerships could broaden its future, but the path depends on clearing tougher approval and reimbursement hurdles.Read more
Theravance Biopharma leans heavily on one lung drug, but signs suggest it could become a go-to option in both hospitals and at home, with a little-noticed path to growth outside the US. The bigger swing comes from a rare-disease drug in late-stage testing that could reshape the company’s future—or fall short and leave it exposed to pricing and competition risks.Read more
Key Takeaways Sustained demand for key therapies and new product approvals support revenue growth, expanded margins, and enhanced operating leverage in both established and emerging markets. Streamlined cost structure, controlled spending, and a robust cash position reduce financial risk while enabling reinvestment in pipeline assets and supporting future earnings growth.Read more
No trending discussion available.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
